Global Vaccines Market Overview, 2023-28

The Global Vaccine market is anticipated to cross USD 105 Billion by 2028 due to growing global health concern and infectious disease rise the demand.

Featured Companies

  • 1. Merck & Co., Inc.
  • 2. GlaxoSmithKline plc.
  • 3. BioNTech SE
  • 4. Bavarian Nordic
  • 5. Bharat Biotech International Limited
  • 6. CSL
  • 7. Charles River Laboratories
  • 8. Creative Biogene
  • 9. Daiichi Sankto Company Ltd
  • More...

Vaccines, also known as immunizations, inject a weakened form of a disease into a person so the body begins producing antibodies or immunity against the disease. Effective immunization has eradicated a number of diseases, such as polio and smallpox, with high death rates. Vaccinations play a crucial role to maintain sustainable health of people across different countries; hence, they are employed in various regional disease-prevention strategies. The demand for vaccinations has increased over the past few years, owing to increase in incidence of both viral and bacterial infectious diseases. Vaccinations are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases. Vaccination is the administration of antigenic components that stimulate protective immunity against a specific infectious agent. The demand for vaccines has increased, owing to high incidences of diseases worldwide. For instance, the Saudi Ministry of Health has recommended influenza vaccination to all the pilgrims traveling to Hajj, especially those tourists who are suffering from chronic illnesses. These vaccines are mandatory for all healthcare professionals who working in the Hajj pilgrimage centers of Mecca and Medina. According to WHO, 325 million people, or roughly 4% of the world's population, live with viral hepatitis and the disease causes 1.34 million deaths per year. The inception of the very first vaccine has completely revolutionized human life in today’s world. Several medical inventions have saved lives, including rotavirus, pneumococcus, varicella, and human papillomavirus (HPV), which would not have been possible without a vaccine. Since 1990, around 122 million children have been saved from polio and other diseases, the Bill & Melinda Gates Foundation. In the last few years, an increasing number of vaccine-related substance registrations have increased steadily, along with an increase in the volume of patents and journals. Vaccine technology has evolved significantly during the last decade, profoundly changing the future of vaccine development. The introduction of genetic engineering has fueled many advances in vaccine development programs, leading to new products. Various virus vaccines that use the attenuated form of the virus have been developed through these methods. Also, new technologies enable the faster detection of viruses and allow for concentration levels to be kept high enough generating an immune response. According to the research report, “Global Vaccine Market Overview, 2023-28” published by Bonafide Research, the market is anticipated to cross USD 105 Billion by 2028, increasing from USD 68.22 Billion in 2022. The market is expected to grow with 7.81% CAGR by 2023-28. There is a continued prevalence of infectious diseases worldwide, some of which lack effective treatments. The need to combat diseases like COVID-19, influenza, HIV/AIDS, tuberculosis, and emerging infectious diseases drives the demand for vaccines. Vaccine manufacturers are developing vaccines for a broader range of diseases, including non-communicable diseases (NCDs) like cancer and autoimmune disorders. These vaccines aim to prevent or treat diseases that were previously untreatable or inadequately addressed, creating new market opportunities. Advances in vaccine development, such as mRNA and vector-based platforms, have reduced the time and cost required for vaccine development. These technologies enable rapid responses to new pathogens, making vaccines a more attractive option for controlling outbreaks. The world's population continues to grow, leading to increased demand for vaccines to protect against preventable diseases. As more people are born and live longer, the need for vaccines to maintain public health and prevent outbreaks remains high. Governments and individuals are spending more on healthcare, including preventive measures like vaccination. The recognition of vaccines as a cost-effective means of disease prevention contributes to their continued growth. Advancements in personalized medicine, including the development of vaccines tailored to an individual's genetic profile, are creating new markets within the vaccine industry. Personalized vaccines have the potential to provide more effective and targeted disease prevention or treatment. Regulatory agencies are streamlining processes to facilitate vaccine development and approval. These efforts reduce the time and cost barriers for manufacturers, encouraging innovation and market growth.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

The global vaccine market is segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa. Among them, Asia-Pacific region is anticipated to grow with over 9% CAGR by 2023-28. The Asia-Pacific region is home to more than half of the world's population, making it a massive market for vaccines. The sheer number of people creates a substantial demand for vaccines to prevent a wide range of infectious diseases. Many countries in Asia-Pacific are increasing their healthcare budgets and infrastructure. This investment includes expanding vaccination programs, introducing new vaccines, and improving cold chain logistics for vaccine distribution. The region faces a significant disease burden from infectious diseases like hepatitis, tuberculosis, dengue, and emerging infectious diseases. The need to control and prevent these diseases through vaccination is driving market growth. Several countries in the Asia-Pacific region have experienced rapid economic growth and an expanding middle class. This leads to increased healthcare spending, including vaccination, as people seek to protect themselves and their families from preventable diseases. Governments in many Asian countries are actively promoting vaccination programs to improve public health. These initiatives include immunization campaigns, funding for research and development, and efforts to increase vaccine accessibility and affordability. Asia-Pacific is a major hub for vaccine manufacturing. Countries like India and China are known for their vaccine production capabilities. They not only meet domestic demand but also export vaccines to other regions, contributing to the region's growth in the global vaccine market. As healthcare infrastructure improves, more people in the Asia-Pacific region have access to healthcare services, including vaccines. This expanded access drives demand for a broader range of vaccines, including those for non-communicable diseases. Based on the technology, live attenuated vaccines are growing with prominent growth rate during the forecast period. Live attenuated vaccines are often highly effective at inducing strong and long-lasting immunity. Because they contain weakened, but still live, forms of the pathogen, they can closely mimic natural infections, stimulating a robust immune response. This results in a more comprehensive and durable immunity compared to some other types of vaccines. Many live attenuated vaccines are administered as a single dose or require fewer booster shots compared to other vaccine types. This makes them particularly valuable in regions with limited healthcare infrastructure or during large-scale vaccination campaigns, as it simplifies vaccination schedules and logistics. Live attenuated vaccines can provide long-lasting protection, sometimes even for a lifetime. This characteristic is especially advantageous for diseases that are challenging to control and require sustained immunity, such as measles and mumps. Some live attenuated vaccines not only protect the vaccinated individual but also reduce the transmission of the disease within communities. For example, the oral polio vaccine can lead to herd immunity by shedding and providing immunity to others, effectively interrupting the spread of the virus. Live attenuated vaccines can be cost-effective because they often require fewer doses and boosters over time. This can result in cost savings for healthcare systems and governments, making them a preferred choice in resource-limited settings. Live attenuated vaccines can be administered through multiple routes, such as oral, intranasal, or intradermal. This flexibility allows healthcare providers to choose the most appropriate method for a specific population or disease. Preventing childhood diseases through vaccination is a top public health priority worldwide. Vaccines have been instrumental in reducing the incidence of many serious and life-threatening diseases in children, such as measles, mumps, rubella, polio, and whooping cough. As such, there is a continued emphasis on expanding pediatric immunization programs to protect children and communities. The success of pediatric vaccines in eradicating or nearly eliminating certain diseases has underscored the value of vaccination. For example, the near-eradication of polio and the significant reduction in cases of measles and rubella are notable achievements driven by pediatric vaccination efforts. International organizations like the World Health Organization (WHO), UNICEF, and Gavi, the Vaccine Alliance, have made significant investments in expanding access to pediatric vaccines in low- and middle-income countries. These initiatives aim to ensure that children in even the most remote areas have access to essential vaccines. Advances in vaccine development and delivery technologies have resulted in safer and more effective pediatric vaccines. For instance, the development of conjugate vaccines has improved protection against diseases like Haemophilus influenzae type b (Hib) and pneumococcal infections. Additionally, the use of micro-needle patches and painless injection devices has made vaccine administration less traumatic for children. Maternal vaccination, where pregnant women are vaccinated to pass on immunity to their infants, is a growing area of interest. Vaccines given to expectant mothers can protect newborns from diseases like influenza, pertussis (whooping cough), and tetanus during the vulnerable early months of life. Pediatricians and healthcare providers play a crucial role in promoting vaccination. They educate parents and caregivers about the importance of immunization and follow vaccination schedules to ensure children receive the recommended vaccines at the appropriate ages.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

The widespread adoption of HPV vaccination has led to significant reductions in cervical cancer rates in countries with robust vaccination programs. These vaccines can potentially lead to the complete eradication of cervical cancer in the long term. Public health authorities and medical professionals widely endorse HPV vaccination as a safe and effective way to prevent HPV infections and their associated health risks. As a result, more individuals are opting to get vaccinated. HPV vaccines are highly effective at preventing HPV infections, including high-risk strains that are linked to various cancers. HPV is the primary cause of cervical cancer, and it is also associated with other cancers, such as anal, oropharyngeal, vaginal, vulvar, and penile cancers. The HPV vaccine helps reduce the risk of these cancers, making it a valuable tool in cancer prevention. HPV vaccines typically provide protection against multiple HPV strains, including those responsible for the majority of HPV-related cancers. For example, the most common HPV vaccines protect against strains 16 and 18, which are responsible for a significant proportion of cervical and other HPV-related cancers. Extensive research and clinical trials have demonstrated the safety of HPV vaccines. This safety record has helped build trust among healthcare providers and the public, leading to greater vaccine acceptance. Many countries have implemented vaccination programs that target adolescents, typically starting between the ages of 9 and 15. These programs ensure that a significant portion of the population is vaccinated early, which is crucial for achieving herd immunity and reducing HPV transmission. Initially, HPV vaccines were primarily recommended for girls and young women to prevent cervical cancer. However, recommendations have expanded to include boys and young men to protect against other HPV-related cancers and to help achieve herd immunity more effectively. Multivalent vaccines, which are vaccines that protect against multiple diseases or strains of a pathogen in a single formulation, are expected to grow during the forecast period. Multivalent vaccines reduce the number of shots needed to protect against multiple diseases. This simplifies vaccination schedules, making it more convenient for individuals and healthcare providers, particularly for children who require numerous vaccinations. Combining multiple vaccines into one shot can increase vaccine coverage rates. When individuals receive vaccines for multiple diseases in a single visit, it reduces the likelihood of missed vaccinations and incomplete immunization. Multivalent vaccines can be cost-effective, both for healthcare systems and individuals. They can reduce the overall cost of vaccine production, storage, transportation, and administration. This is especially beneficial in resource-limited settings where healthcare budgets are constrained. Multivalent vaccines may improve compliance with vaccination recommendations. Fewer shots and clinic visits are more likely to encourage individuals to adhere to recommended vaccination schedules, leading to better public health outcomes. In the case of diseases targeted for eradication or elimination (e.g., polio, measles), multivalent vaccines can play a crucial role. They simplify mass vaccination campaigns, reduce logistical challenges, and contribute to achieving high vaccine coverage rates necessary for disease control. Some diseases, like influenza, can lead to co-infections with other pathogens. Multivalent vaccines that protect against multiple strains of a virus or multiple diseases can help prevent these co-infections, reducing disease severity and complications. For travelers, multivalent vaccines can be especially valuable. Combination vaccines for diseases like hepatitis A and B or typhoid and hepatitis A simplify vaccination regimens for individuals planning to visit areas with increased disease risks. Retail pharmacies are widely accessible to the general population. They have a presence in urban and rural areas, making it easy for people to access vaccines without the need for specialized healthcare facilities. Many retail pharmacies have expanded their vaccine offerings beyond the traditional flu shot to include a wide range of vaccines, including those for COVID-19, travel-related diseases, and routine childhood and adult immunizations. This expanded portfolio provides more options for customers. Retail pharmacies often offer walk-in services, allowing individuals to receive vaccines without an appointment. This flexibility is especially appealing to those with busy schedules or those who may not have a regular healthcare provider. Some retail pharmacies have extended operating hours, including evenings and weekends, which accommodates people varied work schedules and lifestyles. This flexibility ensures that individuals have access to vaccines at times convenient for them. Pharmacists are highly trained healthcare professionals who can provide information and answer questions about vaccines. Their expertise and accessibility make retail pharmacies valuable sources of vaccine information and administration. Many people have established trust in their local retail pharmacies, which can influence their decisions to receive vaccines. Pharmacies often have long-standing relationships with their customers, fostering a sense of familiarity and comfort. Retail pharmacy chains often collaborate with public health agencies and healthcare providers to participate in vaccination campaigns. These partnerships expand vaccine distribution and reach underserved populations. In many countries, retail pharmacies can participate in government-funded vaccination programs. They are reimbursed for administering vaccines, which incentivizes their involvement in public health vaccination efforts. As healthcare systems shift towards preventive care and wellness, retail pharmacies are positioned to provide essential preventive services, including vaccinations. Government policies and regulations often support the involvement of retail pharmacies in vaccine distribution and administration. These policies aim to improve vaccine coverage rates and public health outcomes.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Market Drivers • Rising Demand for Non-Communicable Disease Vaccines: While infectious diseases have traditionally dominated the vaccine market, there is a growing demand for vaccines targeting non-communicable diseases (NCDs) like cancer and autoimmune disorders. Advancements in immunotherapy and the development of therapeutic vaccines are driving this trend. For example, the HPV vaccine for cervical cancer prevention and cancer immunotherapies like checkpoint inhibitors represent areas of expansion within the vaccine market. • Public-Private Partnerships and Funding: Increasingly, governments, non-profit organizations, and pharmaceutical companies are forming public-private partnerships to address vaccine development, distribution, and affordability. These collaborations aim to pool resources, share knowledge, and ensure vaccines reach underserved populations. Initiatives like Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) are examples of these partnerships. Funding mechanisms like advanced market commitments (AMCs) encourage vaccine manufacturers to invest in research and production capacity for diseases affecting low-income countries. Market Challenges • Vaccine Supply Chain Vulnerabilities: The COVID-19 pandemic exposed vulnerabilities in the vaccine supply chain, including raw material shortages, transportation bottlenecks, and manufacturing disruptions. Ensuring a resilient and efficient supply chain, especially for vaccines requiring ultra-cold storage like some mRNA vaccines, remains a significant challenge. Addressing these vulnerabilities involves diversifying supply sources, investing in cold chain infrastructure, and enhancing global coordination. • Vaccine Variants and Evasion: The emergence of new variants of infectious agents poses a challenge to vaccine efficacy. Variants like Delta and Omicron have raised concerns about the need for booster shots and updated vaccines. Vaccine manufacturers must continually adapt their products to address evolving strains. Regulatory agencies must establish streamlined processes for vaccine updates without compromising safety and effectiveness. Market Trends • Personalized Vaccines: Advances in genomics and immunology are paving the way for personalized vaccines tailored to an individual's unique genetic makeup and immune system. Personalized cancer vaccines, for example, are designed to target specific genetic mutations in a patient's tumor cells. This trend holds promise for more effective and targeted treatments, potentially revolutionizing the field of precision medicine. • Global Health Security and Preparedness: The COVID-19 pandemic has highlighted the need for better global health security and preparedness. As a result, there is a growing trend towards establishing stockpiles of vaccines and therapeutics for potential pandemics. Governments and organizations are investing in research, surveillance, and early warning systems to detect and respond to emerging infectious diseases promptly. This trend reinforces the importance of vaccines as a key component of pandemic preparedness. Competitive Landscape The top market players, such as GlaxoSmithKline plc, Sanofi, Pfizer Inc., and Merck & Co., Inc., account for the majority of the market. These companies have a strong product portfolio, the capability of strategic decisions, and focus on resolving the unmet needs in eradicating complex diseases through vaccination. For instance, potential products such as Prevnar 13 of Pfizer and Polio/Pertussis/Hib of Sanofi are leading in the market. Constant exhaustive R&D resulting in approvals and launches of novel products worldwide is expected to maintain their position in the market. Furthermore, increasing demand for injection doses for viral as well as bacterial diseases is anticipated to fuel the company growth and market value in the human industry. Major companies profiled in the market include Merck & Co., Inc, BioNTech SE, Bavarian Nordic, GlaxoSmithKline PLC, Bharat Biotech International Limited , CSL, Charles River Laboratories, Creative Biogene, Daiichi Sankto Company Ltd, Emergent BioSolutions Inc. , Sanofi S.A, Serum Institute of India Pvt. Ltd, Sinovac , AstraZeneca plc , Novavax, Oxford Biomedica, Pfizer Inc, Takeda Pharmaceutical Company Limited, Inovio Pharmaceutical and Walvax Biotechnology Co., Ltd. Key Developments • In September 2021, the Serum Institute of India planned to launch at least one vaccine every quarter beginning with Covishield, which is licensed from AstraZeneca. • In 2021, Abbott launched a new inactivated quadrivalent vaccine for influenza in India that offers protection against four virus strains, in India. • In 2021, GlaxoSmithKline plc announced that they submitted a Biologics License Application (BLA) to the USFDA for its experimental vaccination PRIORIX. Over 100 nations have recently granted licenses for the vaccine, initially registered in Germany. • In 2021, MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme, launched Gardasil 9, India’s first gender-neutral HPV vaccine. Considered in this report: • Geography: Global • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Global Vaccines market Outlook with its value and forecast along with its segments • Region-wise Transformers market analysis • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation Regions covered in the report • North America • Europe • Asia-Pacific • South America • Middle-East & Africa By Technology • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines • Viral vector vaccines • Others By Route of Administration • Intramuscular and subcutaneous administration • Oral administration • Others By End-User Type • Pediatrics • Adults By Disease • Pneumococcal diseases • Cancer • Influenza • Rotavirus • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Shingles • Meningococcal diseases • Hepatitis • Varicella (Chicken Pox) • Mumps • Others By Type • Monovalent vaccines • Multivalent vaccines By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy • Others The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Companies Mentioned

  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • BioNTech SE
  • Bavarian Nordic
  • Bharat Biotech International Limited
  • CSL
  • Charles River Laboratories
  • Creative Biogene
  • Daiichi Sankto Company Ltd
  • Emergent BioSolutions Inc.

Table of Contents

  • Table of Contents
  • 1. Executive Summary
  • 2. Market Dynamics
  • 2.1. Market Drivers & Opportunities
  • 2.2. Market Restraints & Challenges
  • 2.3. Market Trends
  • 2.4. Covid-19 Effect
  • 2.5. Supply chain Analysis
  • 2.6. Policy & Regulatory Framework
  • 2.7. Industry Experts Views
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Market Structure
  • 4.1. Market Considerate
  • 4.2. Assumptions
  • 4.3. Limitations
  • 4.4. Abbreviations
  • 4.5. Sources
  • 4.6. Definitions
  • 5. Economic /Demographic Snapshot
  • 6. Global Vaccines Market Outlook
  • 6.1. Market Size By Value
  • 6.2. Market Share By Region
  • 6.3. Market Size and Forecast, By Geography
  • 6.4. Market Size and Forecast, By Technology
  • 6.5. Market Size and Forecast, By End-User
  • 6.6. Market Size and Forecast, By Distribution Channel
  • 6.7. Market Size and Forecast, By Type
  • 6.8. Market Size and Forecast, By Route of Administration
  • 6.9. Market Size and Forecast, By Disease
  • 7. North America Vaccines Market Outlook
  • 7.1. Market Size By Value
  • 7.2. Market Share By Country
  • 7.3. Market Size and Forecast, By Technology
  • 7.4. Market Size and Forecast, By End-User
  • 7.5. Market Size and Forecast, By Distribution Channel
  • 7.6. Market Size and Forecast, By Type
  • 7.7. Market Size and Forecast, By Route of Administration
  • 7.8. Market Size and Forecast, By Disease
  • 8. Europe Vaccines Market Outlook
  • 8.1. Market Size By Value
  • 8.2. Market Share By Country
  • 8.3. Market Size and Forecast, By Technology
  • 8.4. Market Size and Forecast, By End-User
  • 8.5. Market Size and Forecast, By Distribution Channel
  • 8.6. Market Size and Forecast, By Type
  • 8.7. Market Size and Forecast, By Route of Administration
  • 8.8. Market Size and Forecast, By Disease
  • 9. Asia-Pacific Vaccines Market Outlook
  • 9.1. Market Size By Value
  • 9.2. Market Share By Country
  • 9.3. Market Size and Forecast, By Technology
  • 9.4. Market Size and Forecast, By End-User
  • 9.5. Market Size and Forecast, By Distribution Channel
  • 9.6. Market Size and Forecast, By Type
  • 9.7. Market Size and Forecast, By Route of Administration
  • 9.8. Market Size and Forecast, By Disease
  • 10. South America Vaccines Market Outlook
  • 10.1. Market Size By Value
  • 10.2. Market Share By Country
  • 10.3. Market Size and Forecast, By Technology
  • 10.4. Market Size and Forecast, By End-User
  • 10.5. Market Size and Forecast, By Distribution Channel
  • 10.6. Market Size and Forecast, By Type
  • 10.7. Market Size and Forecast, By Route of Administration
  • 10.8. Market Size and Forecast, By Disease
  • 11. Middle East & Africa Vaccines Market Outlook
  • 11.1. Market Size By Value
  • 11.2. Market Share By Country
  • 11.3. Market Size and Forecast, By Technology
  • 11.4. Market Size and Forecast, By End-User
  • 11.5. Market Size and Forecast, By Distribution Channel
  • 11.6. Market Size and Forecast, By Type
  • 11.7. Market Size and Forecast, By Route of Administration
  • 11.8. Market Size and Forecast, By Disease
  • 12. Competitive Landscape
  • 12.1. Competitive Dashboard
  • 12.2. Business Strategies Adopted by Key Players
  • 12.3. Key Players Market Share Insights and Analysis, 2022
  • 12.4. Key Players Market Positioning Matrix
  • 12.5. Porter's Five Forces
  • 12.6. Company Profile
  • 12.6.1. Merck & Co., Inc
  • 12.6.1.1. Company Snapshot
  • 12.6.1.2. Company Overview
  • 12.6.1.3. Financial Highlights
  • 12.6.1.4. Geographic Insights
  • 12.6.1.5. Business Segment & Performance
  • 12.6.1.6. Product Portfolio
  • 12.6.1.7. Key Executives
  • 12.6.1.8. Strategic Moves & Developments
  • 12.6.2. BioNTech SE
  • 12.6.3. Bavarian Nordic
  • 12.6.4. GlaxoSmithKline PLC
  • 12.6.5. Bharat Biotech International Limited
  • 12.6.6. CSL
  • 12.6.7. Charles River Laboratories
  • 12.6.8. Creative Biogene
  • 12.6.9. Daiichi Sankto Company Ltd
  • 12.6.10. Emergent BioSolutions Inc.
  • 13. Strategic Recommendations
  • 14. Annexure
  • 14.1. FAQ`s
  • 14.2. Notes
  • 14.3. Related Reports
  • 15. Disclaimer
  • ?

List of Table
Table 1 : Global Vaccines Market Snapshot, By Segmentation (2022 & 2028) (in USD Billion)
Table 2 : Influencing Factors for Vaccines Market, 2022
Table 3: Top 10 Counties Economic Snapshot 2020
Table 4: Economic Snapshot of Other Prominent Countries 2020
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Vaccines Market Size and Forecast, By Geography (2017 to 2028F) (In USD Billion)
Table 7 : Global Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 8 : Global Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 9 : Global Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 10 : Global Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 11 : Global Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 12 : Global Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 13 : North America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 14 : North America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 15 : North America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 16 : North America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 17 : North America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 18 : North America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 19 : Europe Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 20 : Europe Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 21 : Europe Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 22 : Europe Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 23 : Europe Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 24 : Europe Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 25 : Asia-Pacific Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 26 : Asia-Pacific Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 27 : Asia-Pacific Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 28 : Asia-Pacific Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 29 : Asia-Pacific Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 30 : Asia Pacific Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 31 : South America Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 32 : South America Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 33 : South America Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 34 : South America Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 35 : South America Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 36 : South America Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)
Table 37 : Middle East & Africa Vaccines Market Size and Forecast, By Technology (2017 to 2028F) (In USD Billion)
Table 38 : Middle East & Africa Vaccines Market Size and Forecast, By End-User (2017 to 2028F) (In USD Billion)
Table 39 : Middle East & Africa Vaccines Market Size and Forecast, By Distribution Channel (2017 to 2028F) (In USD Billion)
Table 40 : Middle East & Africa Vaccines Market Size and Forecast, By Type (2017 to 2028F) (In USD Billion)
Table 41 : Middle East & Africa Vaccines Market Size and Forecast, By Route of Administration (2017 to 2028F) (In USD Billion)
Table 42 : Middle East & Africa Vaccines Market Size and Forecast, By Disease (2017 to 2028F) (In USD Billion)

List of Figures
Figure 1: Global Vaccines Market Size (USD Billion) By Region, 2022 & 2028
Figure 2: Market attractiveness Index, By Region 2028
Figure 3: Market attractiveness Index, By Segment 2028
Figure 4: Global Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 5: Global Vaccines Market Share By Region (2022)
Figure 6: North America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 7: North America Vaccines Market Share By Country (2022)
Figure 8: Europe Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 9: Europe Vaccines Market Share By Country (2022)
Figure 10: Asia-Pacific Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 11: Asia-Pacific Vaccines Market Share By Country (2022)
Figure 12: South America Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 13: South America Vaccines Market Share By Country (2022)
Figure 14: Middle East & Africa Vaccines Market Size By Value (2017, 2022 & 2028F) (in USD Billion)
Figure 15: Middle East & Africa Vaccines Market Share By Country (2022)
Figure 16: Competitive Dashboard of top 5 players, 2022
Figure 17: Market Share insights of key players, 2022
Figure 18: Porter's Five Forces of Global Vaccines Market

Feed Phosphate Market Research FAQs

Major vaccine manufacturers include Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Sanofi Pasteur, GlaxoSmithKline (GSK), Novartis, Merck & Co., Inc., and Sinovac, among others.

Vaccines are available in various types, including live attenuated vaccines, inactivated vaccines, subunit vaccines, conjugate vaccines, recombinant vaccines, and toxoid vaccines, each designed to prevent specific diseases.

Regulatory agencies like the FDA in the United States and the EMA in Europe assess the safety and efficacy of vaccines, granting approvals for their use. They play a critical role in ensuring vaccine quality and safety.

Vaccine distribution involves complex supply chains to deliver vaccines from manufacturers to healthcare providers. Distribution often includes government programs, healthcare facilities, pharmacies, and international organizations.

Challenges include vaccine hesitancy, access disparities, supply chain issues, research funding, emerging diseases, regulatory hurdles, and the need for equitable distribution, particularly in low-income countries.

The COVID-19 pandemic accelerated vaccine development efforts. Multiple vaccines, including mRNA vaccines, were developed in record time. Distribution challenges and global access have also been significant issues during the pandemic.
Logo

Global Vaccines Market Overview, 2023-28

Contact usWe are friendly and approachable, give us a call.